Takashi Kawahara1, Hiroki Ide2, Eiji Kashiwagi2, Kareem A El-Shishtawy2, Yi Li3, Leonardo O Reis2, Yichun Zheng1, Hiroshi Miyamoto4. 1. Department of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY. 2. Department of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD. 3. Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY. 4. Department of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY. Electronic address: hiroshi_miyamoto@urmc.rochester.edu.
Abstract
PURPOSE: Emerging preclinical evidence suggests that androgen-mediated androgen receptor (AR) signals promote bladder cancer progression. However, little is known about the efficacy of an AR signaling inhibitor, enzalutamide, in the growth of bladder cancer cells. In this study, we compared the effects of enzalutamide and 2 other classic antiandrogens, flutamide and bicalutamide, on androgen-induced bladder cancer cell proliferation, migration, and invasion as well as tumor growth in vivo. METHODS: Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist. We also used a mouse xenograft model for bladder cancer. RESULTS: Dihydrotestosterone increased bladder cancer cell proliferation, migration, and invasion indicating that endogenous or exogenous AR was functional. Enzalutamide, hydroxyflutamide, and bicalutamide showed similar inhibitory effects, without significant agonist activity, on androgen-mediated cell viability/apoptosis, cell migration, and cell invasion in AR-positive lines. No significant effects of dihydrotestosterone as well as AR antagonists on the growth of AR-negative cells were seen. Correspondingly, in UMUC3 cells, these AR antagonists down-regulated androgen-induced expression of AR, matrix metalloproteinase-2, and interleukin-6. Androgen-enhanced AR-mediated transcriptional activity was also blocked by each AR antagonist exhibiting insignificant agonist activity. In UMUC3 xenograft-bearing mice, oral gavage treatment with each antiandrogen retarded tumor growth, and only enzalutamide demonstrated a statistically significant suppression compared with mock treatment. CONCLUSIONS: Our current data support recent observations indicating the involvement of the AR pathway in bladder cancer growth and further suggest that AR antagonists, including enzalutamide, are of therapeutic benefit in AR-positive bladder cancer.
PURPOSE: Emerging preclinical evidence suggests that androgen-mediated androgen receptor (AR) signals promote bladder cancer progression. However, little is known about the efficacy of an AR signaling inhibitor, enzalutamide, in the growth of bladder cancer cells. In this study, we compared the effects of enzalutamide and 2 other classic antiandrogens, flutamide and bicalutamide, on androgen-induced bladder cancer cell proliferation, migration, and invasion as well as tumor growth in vivo. METHODS: Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist. We also used a mouse xenograft model for bladder cancer. RESULTS:Dihydrotestosterone increased bladder cancer cell proliferation, migration, and invasion indicating that endogenous or exogenous AR was functional. Enzalutamide, hydroxyflutamide, and bicalutamide showed similar inhibitory effects, without significant agonist activity, on androgen-mediated cell viability/apoptosis, cell migration, and cell invasion in AR-positive lines. No significant effects of dihydrotestosterone as well as AR antagonists on the growth of AR-negative cells were seen. Correspondingly, in UMUC3 cells, these AR antagonists down-regulated androgen-induced expression of AR, matrix metalloproteinase-2, and interleukin-6. Androgen-enhanced AR-mediated transcriptional activity was also blocked by each AR antagonist exhibiting insignificant agonist activity. In UMUC3 xenograft-bearing mice, oral gavage treatment with each antiandrogen retarded tumor growth, and only enzalutamide demonstrated a statistically significant suppression compared with mock treatment. CONCLUSIONS: Our current data support recent observations indicating the involvement of the AR pathway in bladder cancer growth and further suggest that AR antagonists, including enzalutamide, are of therapeutic benefit in AR-positive bladder cancer.
Authors: Francesca Sanguedolce; Luigi Cormio; Giuseppe Carrieri; Beppe Calò; Davide Russo; Andrea Menin; Antonio Luigi Pastore; Francesco Greco; Giorgio Bozzini; Antonio Galfano; Giovannalberto Pini; Angelo Porreca; Filippo Mugavero; Mario Falsaperla; Carlo Ceruti; Luca Cindolo; Alessandro Antonelli; Andrea Minervini Journal: Histol Histopathol Date: 2019-12-05 Impact factor: 2.303
Authors: Daoshan Zheng; Cecilia Williams; Jeremy A Vold; Justin H Nguyen; Denise M Harnois; Sanjay P Bagaria; Sarah A McLaughlin; Zhaoyu Li Journal: Cancer Lett Date: 2018-09-14 Impact factor: 8.679
Authors: Kimberley Katleba; Alan P Lombard; Maria-Malvina Tsamouri; Han Bit Baek; Kristine S Nishida; Stephen J Libertini; Alexander J Platero; Ai-Hong Ma; Chong-Xian Pan; Paramita M Ghosh; Maria Mudryj Journal: Cancer Lett Date: 2021-02-04 Impact factor: 8.679